Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates

Core Insights - Johnson & Johnson reported quarterly earnings of $2.8 per share, exceeding the Zacks Consensus Estimate of $2.77 per share, and showing an increase from $2.42 per share a year ago, representing an earnings surprise of +1.08% [1] - The company achieved revenues of $23.99 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.03% and increasing from $22.47 billion year-over-year [2] - Johnson & Johnson's stock has increased approximately 32% since the beginning of the year, outperforming the S&P 500's gain of 13.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes in these expectations [4] - The current consensus EPS estimate for the next quarter is $2.56 on revenues of $24.03 billion, and for the current fiscal year, it is $10.86 on revenues of $93.43 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]